Insider sales post-acquisition close are likely profit-taking, not a fundamental signal. Monitor for additional filings; the next 10-Q will update on deal integration. No immediate trading action warranted.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $156.50entry
- T+1 · 6mo ago −0.50%α −1.08% · $155.72
- T+5 · 6mo ago +2.54%α +0.89% · $160.48
- T+20 · 5mo ago +3.27%α +3.44% · $161.62
- T+60 · 3mo ago −1.45%α −4.37% · $154.23
Price Chart
How similar events traded
Executive Summary
Two directors sold $40.2M in NBIX shares ($2.36M and $37.82M) within days of Neurocrine's $2.9B acquisition of Soleno Therapeutics closing on May 18, 2026. The sales represent 0.26% of market cap and follow option exercises by the same insiders, indicating routine profit-taking post-deal rather than a bearish signal.
Key Financial Metrics
Key Facts
- Directors Richard F. Pops and Kevin Charles Gorman sold a combined $40.2M in open-market sales on May 15 and May 19, 2026.
- Sales occurred after the close of Neurocrine's $2.9B acquisition of Soleno Therapeutics on May 18, 2026.
- The total sale value is 0.26% of NBIX's $15.6B market cap, a modest amount.
- Both insiders also exercised stock options around the same dates, converting non-cash awards into shares sold.
Financial Impact
$40.2M in insider sales, 0.26% of market cap
Risk Factors
- Further insider selling could appear, but at current magnitude it is not material.
- Integration of Soleno's VYKAT XR may face commercial hurdles not yet reflected in insider behavior.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1779405695847 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers